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Introduction
Sorafenib (Fig. 1) , an orally active multikinase inhibitor, blocks tumor cell proliferation by targeting Raf/MEK/ERK, and exerts an antiangiogenic effect by targeting vascular endothelial growth factor receptor-1/-2/-3 (VEGFR-1/-2/-3), and platelet derived growth factor receptor beta (PDGFR-β) tyrosine kinases (Wilhelm et al., 2004) .
Sorafenib is approved for the treatment of renal and hepatocellular carcinomas, and has demonstrated activity towards other malignancies (Ratain et al., 2006; Miller et al., 2009 ).
Following oral administration of [
14 C]sorafenib to healthy volunteers, approximately 77% of a 100 mg oral dose was excreted in feces (51% as parent), and 19% of the dose was excreted in urine as glucuronidated metabolites; approximately 17% of circulating radioactivity in plasma was in the form of sorafenib N-oxide (Lathia et al., 2006) . Sorafenib oxidative metabolism is mediated by cytochrome P450 3A4 (CYP3A4) yielding the N-oxide sorafenib metabolite. Sorafenib also undergoes glucuronidation by the uridine disphosphate-glucuronyl-transferase (UGT1A9) pathway (Fig 1; Lathia et al., 2006) . Peak plasma concentrations of sorafenib occur within 2 to 3 hours after a single, oral dose (Strumberg et al., 2005) pharmacokinetics can be caused by inter-individual differences in the metabolizing enzymes and/or the transport proteins, which also have been shown to be subject to polymorphisms. Understanding the mechanisms of hepatic uptake and the extent of biliary excretion of sorafenib is particularly important in patients with unresectable hepatocellular carcinoma, where the target site of sorafenib is the liver.
Transport proteins can play an important role in the clearance of drugs from hepatic sinusoidal blood, and the excretion of parent drug and/or metabolite(s) across the apical membrane into the bile canaliculus. The basolateral proteins that mediate uptake of endogenous and exogenous compounds into hepatocytes include members of the solute carrier (SLC) superfamily: Na + -taurocholate co-transporting polypeptide (NTCP), organic anion transporters (OATs), organic cation transporters (OCTs), and organic anion transporting polypeptides (OATPs). NTCP, which is expressed exclusively in the liver, is Na + -dependent and predominately accounts for uptake of bile acids (Ho et al., 2004) . Recently, a few drugs such as rosuvastatin have been reported to be NTCP substrates (Ho et al., 2006) . The OATPs exhibit broad and overlapping substrate specificity, and display an affinity for organic anions as well as some bulky cations and neutral steroids (Mikkaichi et al., 2004) . In contrast to NTCP, the OATPs operate in a Na + -independent manner, and have been shown to function as bidirectional carriers (Li et al., 2000; Briz et al., 2006; Mahagita et al., 2007) . There are three human isoforms, OATP1B1, 1B3 and 2B1, that play a substantial role in hepatic uptake of many endogenous and exogenous compounds including bilirubin (Konig et al., 2000; Cui et al., 2001) , fexofenadine (Cvetkovic et al., 1999) and many statins (Shitara and Sugiyama, 2006) . OCTs are electrogenic uniporters that primarily mediate transport of
small cations, although transport of anions and uncharged compounds has been reported (Koepsell et al., 2003) . The OATs constitute a family of proteins that mediate transport of negatively charged endogenous and exogenous compounds in exchange for dicarboxylate ions. OATs are predominantly expressed in the kidney, although OAT2 has higher expression on the sinusoidal membrane of hepatocytes compared to the basolateral membrane of proximal kidney tubules (Sun et al., 2001) . Transporters located in the apical membrane involved in the removal of drug and/or metabolite(s) into the bile canaliculus include P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP2), breast cancer resistance protein (BCRP) and the bile salt export pump (BSEP). Sorafenib is a weak substrate for P-gp, but the overall effect of this transporter on plasma concentrations is low based on in vivo results utilizing mdr1a/1b(-/-) knockout mice (Gnoth et al., 2010) .
The objective of the present study was to identify whether transport proteins are involved in the hepatic uptake of sorafenib, and to determine the extent of biliary excretion of sorafenib and its metabolites in human hepatocytes. Initial uptake was assessed in freshly isolated human hepatocytes and in OCT1 transfected CHO cells.
Sandwich-cultured human hepatocytes were utilized to determine the hepatobiliary disposition of sorafenib and metabolites. choline; pH = 7.4) and stored on ice prior to conducting uptake studies (Leslie et al., 2007) . Isolated hepatocytes were suspended in the same buffer (1 x 10 6 cells/ml), placed on ice, and used immediately in experiments. Hepatocyte suspensions (1 ml; n = 2 livers, in triplicate) were pre-incubated in 16 x 100 mm glass test tubes at 37˚C for 3 min; 0.1% DMSO or chemical inhibitor was added 1 min before [ (Baur et al., 1975) . Protein concentrations for individual hepatocyte suspensions were determined with the BCA protein assay reagent kit (Pierce) as instructed by the manufacturer. BSA, as supplied by the manufacturer, was used as a standard (0.2 -1 mg/mL).
Transport Studies in hOCT1-Expressing CHO Cells Transport studies were carried out five days post-seeding, as previously described (Ming et al., 2009) (Table 1) were seeded ~1.75 x 10 6 cells/well on 6-well BioCoat ™ plates in DMEM without phenol red supplemented with 2 mM L-glutamine, 1% (v/v) MEM nonessential amino acids, 100 units penicillin G sodium, 100 µg streptomycin sulfate, 1 µM dexamethasone, 5% (v/v) FBS, and 10 µM insulin (day 0 of culture), and allowed to attach for 2-6 h in a humidified incubator (95% O 2 , 5% CO 2 ) at 37 º C. After cell attachment, culture plates were swirled gently and the culture medium was replaced with the same medium. Cells were overlaid 16-24 h (day 1 of culture) after seeding with ice-cold Matrigel ™ basement membrane matrix (0.25 mg/mL) in 2 mL/well cold serumfree DMEM containing 2 mM L-glutamine, 1% (v/v) MEM non-essential amino acids, 100 units penicillin G sodium, 100 µg streptomycin sulfate, 1 µM dexamethasone, and
The culture medium was changed every 24 h until experiments were performed on day 7 of culture.
Accumulation Studies
The method to determine substrate accumulation in sandwichcultured hepatocytes has been described previously (Leslie et al., 2007; Wolf et al., 2008) . Cells were incubated for 20 min at 37 º C with 1.5 mL of sorafenib solution (1 and 10 µM). Medium samples were collected immediately, and hepatocytes were rinsed vigorously three times with 2 mL ice-cold standard buffer following the incubation. coupled to an Agilent 1200 system (Waldbronn, Germany). Sorafenib and its metabolites were eluted from a Synergi Hydro RP 2.5 µm column (20 x 2 mm i.d.,
Phenomenex, Torrance, CA, USA) using a mobile phase gradient at a flow rate of 0.3 mL/min (A: 0.05% formic acid in water, B: 0.05% formic acid in acetonitrile); 0 min 30% B, 5 min 60% B, 5.3 min 30% B. The column effluent was monitored using a LTQ Orbitrap XL (Thermo Scientific, Bremen, Germany) by quantification of the exact mass of sorafenib, internal standard, sorafenib N-oxide and sorafenib glucuronide. The calibration ranged from 1 ng/ml to 1000 ng/ml. The LLOQ for sorafenib was 2 ng/ml and 1 ng/ml for sorafenib N-oxide. (Fig. 2.A and B). Uptake at 4°C was reduced by ~61-63% of the uptake at 37°C (Fig.2.A -D) . (Fig.3.A) . transfected and mock CHO cells, suggesting that other MPP + sensitive transport processes are involved in sorafenib uptake (Fig.3.B) . [ 14 C]Sorafenib uptake in mock cells was reduced to ~49-63% by MPP + , suggesting that passive diffusion plays a role in sorafenib uptake, consistent with data generated in suspended human hepatocytes at 4°C.
Data Analysis

Hepatobiliary Dispostion of Sorafenib in Human Sandwich-Cultured Hepatocytes
The hepatobiliary disposition of [ (Table 1) were consistent with previous data generated in this model system. The cellular accumulation of sorafenib appeared to be dose-dependent (Table 2) Table 2 ).
The BEI of sorafenib in sandwich-cultured human hepatocytes was low (~11%).
The sorafenib in vitro Cl biliary was moderately low at 1 and 10 µM sorafenib (~11 mL/min/kg), ranging from approximately one-third to one-fifth of the taurocholate in vitro
Cl biliary values in each of the liver donors (Tables 1 and 2 ). After a 20-min incubation with either 1 or 10 µM sorafenib, sorafenib N-oxide concentrations were below the detection limit (<1 ng/mL) in medium, except for the 10 µM dose in hepatocytes prepared from the second liver; however, longer incubation times of 60 and 120 min resulted in slightly higher medium concentrations of sorafenib N-oxide (Fig.4) . 
Discussion
Hepatic transport proteins are recognized increasingly as important determinants of the pharmacokinetics of many drugs, as well as key sites of drug-drug interactions (Soars et al., 2009) . Genetic polymorphisms of uptake transport proteins also have been implicated in inter-individual differences in the pharmacokinetics and pharmacodynamics of clinically relevant drugs such as the statins (Ieiri et al., 2009 ). In the present study, the transport proteins involved in the hepatic uptake of sorafenib were investigated, and the hepatobiliary disposition of sorafenib and metabolites was assessed.
Sorafenib is a very lipophilic compound (log D 7 = 5.16; predicted properties SciFinder Scholar version 2007). The initial uptake of sorafenib in human hepatocytes was examined at 37°C vs. 4°C to assess the contribution of passive diffusion to overall uptake. The initial uptake of [ 14 C]sorafenib at 4°C was reduced 61 and 63% at 0.5 and 1.5 min, respectively, compared to 37°C, which suggests a high degree of passive diffusion ( Fig. 2.A -C) . The contribution of passive diffusion vs carrier mediated uptake remains unclear due to the effect of temperature on both processes. There was also a high degree of passive diffusion in CHO cells (Fig. 3.B) . (Swift et al., 2010) . Sorafenib uptake at all timepoints sampled was sensitive to rifamycin SV and decynium 22, suggesting that the OATPs and OCTs are involved in the hepatic uptake this tyrosine kinase inhibitor (Fig. 2.C and D) . Contribution of OATP1B1 and OATP1B3
to the hepatic uptake of sorafenib has been confirmed in vitro (Zimmerman et al., 2013) .
The involvement of OCT1 in sorafenib uptake was investigated further using a hOCT1-expressing CHO cell line. This finding contradicts work by Hu et al., who reported no appreciable uptake of sorafenib by X. laevis oocytes expressing OCT1, OATP1A2, OATP1B1 or OATP1B3 (Hu et al., 2009 conclusively demonstrated transport of sorafenib by Bcrp both in vitro and in vivo, in contrast to the data generated in LLC-PK1 cells transfected with BCRP (Hu et al., 2009; Agarwal et al., 2011) . Imatinib, another tyrosine kinase inhibitor, is an OCT1 substrate in the human T-lymphoblastoid cell line CCRF-CEM (Thomas et al., 2004) . Some substrate overlap exists between OCTs and OATPs, which have affinity for numerous type II (bulky) cations such as N-methylquinine (van Montfoort et al., 1999) .
Furthermore the class of tyrosine kinase inhibitors has been shown to inhibit metformin uptake in OCT transfected cell lines (Minematsu and Giacomini, 2011) .
Decynium 22 inhibition of sorafenib uptake in suspended human hepatocytes was likely due to OCT1 based on further studies demonstrating that OCT1-mediated uptake of sorafenib was significantly higher in hOCT1-transfected CHO cells compared to mock cells over the concentration range examined (0.5 to 5 µM; Fig 3B) 
used in these studies were in the range of the reported total maximum plasma concentration (5 to 21 µ M) after multiple oral doses of sorafenib (100 to 600 mg twice daily) (Strumberg et al., 2005) , but higher than the expected unbound plasma concentration of sorafenib based on reported binding to plasma proteins (99.5% bound; package insert). Sorafenib, a P-gp and Bcrp substrate (Hu et al., 2009; Gnoth et al., 2010; Agarwal et al., 2011) , exhibited a relatively low BEI (up to 11%; Table 2 ) and in vitro Cl biliary (up to 11.5 ml/min/kg), which is not surprising due to the extent of CYP3A4-and UGT1A9-mediated metabolism observed in vivo (Lathia et al., 2006) . The model
testosterone 6β-hydroxylation formation (LeCluyse et al., 1996) . Sorafenib N-oxide is the primary circulating metabolite in human plasma (Lathia et al., 2006) ; concentrations of sorafenib N-oxide in medium, a surrogate for blood, increased with the longer incubation times. Although no glucuronide was detected in the bile of sandwichcultured hepatocytes after a 20-min incubation, sorafenib glucuronide was excreted into bile after incubation of hepatocytes with sorafenib for 60 and 120 min, as demonstrated with the higher BEI (40-42%; Fig. 4 ). The increased formation and biliary excretion of sorafenib glucuronide after longer incubation times may partially explain the significant amount of parent drug recovered in feces after oral dosing [~77% of a 100 mg oral dose was excreted in feces, of which 51% was the parent drug (package insert)]. Based on our results, we hypothesize that sorafenib glucuronide undergoes biliary excretion, a portion of the glucuronide conjugate is cleaved in the gastrointestinal tract and subsequently, generated sorafenib is reabsorbed. This hypothesis is supported by the clinical observation of secondary peaks in the sorafenib plasma concentration-time profile (Lathia et al., 2006) . Sorafenib glucuronide also was detected in the medium of sandwich-cultured hepatocytes (Fig. 4) , in agreement with the findings that glucuronidated metabolites of sorafenib are recovered in human urine after oral administration.
Sorafenib metabolites, specifically the glucuronide conjugates, require transport proteins for biliary excretion and basolateral efflux. As mentioned sorafenib is a P-gp and Bcrp substrate, and may also be an MRP2 substrate (Shibayama et al., 2011), suggesting that these transport proteins may play a role in the biliary excretion of sorafenib and/or metabolites. MRP2 is responsible for the biliary excretion of many
glucuronide conjugates of drugs, as well as bilirubin conjugates (Kamisako et al., 1999) , and may transport sorafenib glucuronide into bile. Clinically relevant drug interactions associated with impaired biliary clearance have been reported for digoxin due to coadministration of the P-gp inhibitors quinidine, verapamil and ritonavir (Fenner et al., 2009 ). Furthermore, it is well recognized that patients with liver disease develop adaptive changes in transport protein expression, which protect the hepatocyte from the intracellular accumulation of toxic compounds such as bile acids. In fact, many patients with hepatocellular carcinocma develop cirrhosis, which results in down-regulation of basolateral uptake transport proteins often coupled with up-regulation of canalicular and basolateral efflux proteins (Zollner et al., 2003; Zollner et al., 2007) . This highlights the importance of understanding the mechanisms of sorafenib hepatobiliary disposition.
In conclusion, sorafenib uptake in suspended human hepatocytes, CHO cells and sandwich-cultured human hepatocytes was extensive. Uptake into human hepatocytes was temperature dependent and decreased ~61-63% at 4°C, suggesting a high degree of passive diffusion. The active portion of hepatic uptake was sensitive to rifamycin SV and decynium 22. OCT1-mediated uptake of sorafenib was confirmed in µ M) at 0.5 min (C) and 1.5 min (D) in suspended human hepatocytes incubated at 37°C in standard buffer, unless otherwise specified, and in the presence of transport protein modulators including choline buffer, inhibitors (rifamycin SV, decynium 22, and ketoprofen) and lower incubation temperature (n=2 livers; mean percentage ± range). 
